Save the Date: Press Briefing on Clinical Advances in Focused Ultrasound - Revolutionary Non-Invasive Therapy Shows Promise Treating Brain, Cancers, and Pain
Source Newsroom: Focused Ultrasound Foundation
Save the Date!
Tuesday, October 14, 2014
12:00 – 1:30 pm
Press Briefing on Clinical Advances in Focused Ultrasound
Revolutionary Non-Invasive Therapy Shows Promise Treating Brain, Cancers, and Pain
Bethesda North Marriott Hotel & Conference Center
A press briefing will be conducted featuring key data presented at the 4th International Symposium on Focused Ultrasound. Global experts will highlight advances in the use of focused ultrasound – a non-invasive therapeutic technology – to treat brain disorders, cancers and pain, as well as share promising data on several emerging applications.
The event will be webcast for those unable to attend in person.
Featured Speakers Include:
Dr. Andrew von Eschenbach
Former Commissioner of the Food and Drug Administration and
Former Director of the National Cancer Institute
Dr. Neal F. Kassell
Chairman, Focused Ultrasound Foundation
Dr. Mark Hurwitz
Director of Thermal Oncology of the Department of Radiation Oncology
Thomas Jefferson University and Hospital
Dr. Alessandro Napoli
Department of Radiological, Oncological and Pathological Sciences
Sapienza University of Rome
The 4th International Symposium on Focused Ultrasound is the world's leading forum for sharing the latest translational and clinical advances in image-guided focused ultrasound. The symposium will spotlight breakthrough preclinical, translational and clinical research related to one of today’s most promising and innovative therapeutic technologies.
About Focused Ultrasound Technology
Focused ultrasound is a revolutionary, early-stage therapeutic technology with the potential to transform the treatment of many serious medical disorders. This breakthrough technology uses ultrasonic energy guided by magnetic resonance or ultrasound imaging to treat tissue deep in the body without incisions or radiation.
Focused ultrasound is currently approved in the U.S. to treat uterine fibroids and bone metastases, and there are a growing number of clinical applications in various stages of research and development around the world, including Parkinson’s disease, essential tremor, neuropathic pain, breast and prostate cancer, and brain tumors.
To RSVP, contact: Susan Klees at: email@example.com